![]() ![]() In the analysis of T cells, natively paired a/b TCR sequences and single cell phenotypes were generated for 3,119 PD1 + T cells. Such tumor-specific Abs could form the basis of new cancer therapies. Several Abs were identified that bind specifically to breast tumor but not to adjacent breast tissue. These Abs were screened for binding to non-autologous breast tumor sections. By selecting Ab sequences and expressing them as recombinant proteins, patient-derived Abs were identified that bind to cancer cell lines. We sought similar Abs that had arisen independently in different donors by convergent selection, and identified 12 sets of Abs, each of which comprised sequences from more than one donor. 931 of these families had two or more cells. ![]() ![]() Abs were grouped into putative clonal families based on germline gene usage and other sequence features. Results: A total of 9160 expression-ready, native pairs of heavy and light immunoglobulin chains were identified. Methods: Using Immune Repertoire CaptureĀ® (IRCā¢) technology to study single cells from peripheral blood, paired chain IgG antibody (Ab) sequences were generated from plasmablasts, and paired chain a/b TCR sequences were generated from PD1 + T cells along with phenotypic profiles for HLA-DR, CD38 and TIGIT. These patients had diverse hormone receptor status, HER2 status, and treatment history. We studied the B and T cell responses of 11 metastatic breast cancer (MBC) patients who had exceptional responses to systemic therapy with multi-year benefit, all of whom were disease-free or long-term progression-free. Background: Analyzing anti-cancer immune responses can offer insights into the mechanisms that underlie successful cancer therapies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |